– Sanford Heisler Kimpel, LLP today announced that genetic testing giant Pathway Genomics Corporation has agreed to settle a qui tam suit and pay the United States government, 29 states and the District of Columbia $4.1 million dollars.
Sanford Heisler Kimpel, along with Aashish Y. Desai of the Desai Law Firm, P.C., represented Relator Monique Gipson, who sued San Diego-based Pathway Genomics in the U.S. District Court for the Southern District ofCalifornia under the whistleblower provisions of the federal False Claims Act, the federal Anti-Kickback Statute, and the relevant provisions of the false claims acts of the states and the District of Columbia pertaining to healthcare fraud. Gipson was a former sales representative at Pathway Genomics with first-hand knowledge of the company’s wrongdoing. read more
Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University
/PRNewswire/ — Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed. read more
BioTE® Medical Study Showing Promising Results for Military Veterans Diagnosed with PTSD and TBI
/PRNewswire/ — A current BioTE® Medical Combat Trauma Treatment Study (in conjunction with the Veterans Advocacy Center (VAC)) is showing promising results in helping veterans suffering from Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).
Founder of BioTE® Medical, Gary Donovitz, M.D., explains it this way: “Many veterans return from combat with PTSD and TBI. They have hormone imbalances that start in the pituitary gland. We are optimizing their hormones to help relieve their symptoms naturally. We do this by using bioidentical hormones instead of conventional prescription medication. This can improve the quality of their lives.” read more
DATATRAK Technology and Clinical Research Expertise Bests Competitors
PRNewswire/ — DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies and delivering related services for the clinical trials industry, today announced top ranking content in the Clinical Leader Top 10 of 2015. A total of 5 DATATRAKauthored articles were highlighted in the annual recap, more than any other source, with top spots in the White Paper and Case Study categories. read more
NeoGenomics Completes Acquisition of Clarient, Inc.
PRNewswire/ — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of Clarient, Inc. and its wholly-owned subsidiary Clarient Diagnostic Services, Inc. Clarient, a provider of comprehensive cancer diagnostic testing to hospitals, physicians and the pharmaceutical industry, was a unit of GE Healthcare’s Life Sciences business. Based in Aliso Viejo, California and Houston, Texas, Clarient has approximately 415 employees and reported 2014 revenue of approximately $127 million. read more
Acerus Announces Termination of NATESTO™ Agreement with Endo
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP) today announced that the agreement with Endo Ventures Bermuda Limited (an affiliate of Endo International plc) relating to the commercialization of NATESTO™ in the United States and Mexico will be terminated, effective June 30, 2016. read more